MitraClip System (Abbott Vascular) success in EVEREST II trial for reatment of Mitral Regurgitation

Abbott announced data from the EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High Surgical Risk cohort evaluating the company's first-in-class catheter-based MitraClip System for the treatment of Mitral Regurgitation (MR). Findings were presented at the 62nd Annual Scientific Session of the American College of Cardiology in San Francisco

Results showed: A 30-day mortality rate significantly lower than expected for surgery (4.8 percent for patients treated with the MitraClip system versus 18.2 percent predicted surgical mortality, p<0.0001); a low rate of adverse events despite the high surgical risk profile of the patients an implant success rate of 96 percent acute reduction in mr to 2 or less achieved in 86 percent of patients treated with the mitraclip device clinically significant improvement in left ventricular size significant improvements in nyha functional class and sf-36 quality of life scores and significantly reduced rates of hospitalization for heart failure 48 percent reduction from one year post-discharge compared to the year prior to treatment p><0.0001).>